Metastatic Breast Cancer


Kisqali® Receives FDA Approval as First Line Treatment for HR+/HER2- Metastatic Breast Cancer (March 16, 2017)

The US Food and Drug Administration (FDA) has approved the investigational drug Kisqali® (ribociclib, LEE011) for first line treatment of hormone receptor + HER 2- metastatic breast cancer because when... Continue Reading

Ribociclib Offers ‘Paradigm Shift’ in Advanced Breast Cancer (October 26, 2016)

The investigational drug ribociclib (formerly LEE011) when combined with Femera (letrozole) for the initial treatment of postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer... Continue Reading

Metastatic Breast Cancer- Ask the Expert, Your Questions Answered (October 11, 2016)

Ask the Expert session with Memorial Sloan Kettering Cancer Center’s Chau T. Dang, MD Dr. Dang discussed advances in the management of metastatic breast cancer and answered your questions in a live... Continue Reading

Breast Cancer Awareness Month: Ask Questions, Get Connected (October 1, 2016)

What does breast cancer awareness month mean to you? We’d like to hear from you—join us on facebook, twitter, or CancerConnect and join the discussion. On October 10th  at 6pm EDT, we will have... Continue Reading

ASCO Treatment Recommendations for HR+, Metastatic Breast Cancer (September 5, 2016)

The American Society of Clinical Oncology (ASCO) recently convened an Expert Panel to create recommendations for endocrine therapy for women with hormone-receptor (HR)-positive, metastatic breast cancer.... Continue Reading

Ribociclib Receives FDA Breakthrough Therapy Designation as First-line Treatment for HR+/HER2- Advanced Breast Cancer (August 3, 2016)

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ribociclib (LEE011) in combination with Femara® (letrozole) for the treatment of hormone receptor positive, human... Continue Reading

Directly Involving Patients Drives Participation in Metastatic Breast Cancer Study (June 22, 2016)

A clinical study to accelerate research in metastatic breast cancer has rapidly enrolled participants through direct collaboration with patients. These results were recently presented at the 2016 annual... Continue Reading

Abemaciclib Promising in Advanced Breast Cancer (June 7, 2016)

The investigative agent abemaciclib, which is still in clinical trials, appears promising in providing anti-cancer activity among patients with metastatic breast cancer that has progressed following several... Continue Reading

Dose-Dense Chemotherapy for Premenopausal Breast Cancer Improves Survival (March 28, 2016)

Premenopausal women who have been diagnosed with breast cancer have improved survival if their chemotherapy doses are delivered every two weeks, compared to every three weeks. These results were recently... Continue Reading

Ibrance® Approved for Use in Combination with Faslodex® in Hormone-Positive Breast Cancer (March 17, 2016)

The United States Food and Drug Administration (FDA) has approved Ibrance (palbociclib) to be used with Faslodex (fulvestrant) for women with hormone-positive (HR-positive), human epidermal growth factor... Continue Reading

ASCO Publishes Breast Cancer Survivorship Guidelines (January 25, 2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated... Continue Reading

Conjugate Drug Extends Survival in Patients with Advanced HER2-Positive Breast Cancer (January 6, 2016)

Patients with metastatic, HER2-positive breast cancer received a combination antibody/chemotherapy drug in a phase 3 clinical trial survived longer, on average, than patients receiving other treatments.... Continue Reading

Adding Carboplatin to Pre-surgery Chemotherapy Improves Survival for Patients with Triple-Negative Breast Cancer (December 22, 2015)

Adding carboplatin to pre-surgery chemotherapy improved disease-free survival for patients with triple-negative breast cancer (TNBC), according to results from a German clinical study released at the San... Continue Reading

Adding Carboplatin to Pre-surgery Chemotherapy Improves Survival for Patients with Triple-Negative Breast Cancer (December 21, 2015)

Adding carboplatin to pre-surgery chemotherapy improved disease-free survival for patients with triple-negative breast cancer (TNBC), according to results from a German clinical study released at the San... Continue Reading

Abemaciclib Receives FDA Breakthrough Therapy Designation in Advanced Breast Cancer (October 9, 2015)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to abemaciclib, a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, for patients with refractory hormone-receptor-positive... Continue Reading

No Benefit with Addition of Onartuzumab to Taxol® with or without Avastin® in Triple-Negative Breast Cancer (September 29, 2015)

The addition of the targeted therapy onartuzumab to Taxol® (paclitaxel) with or without Avastin® (bevacizumab) does not appear to help control disease or improve survival in patients with metastatic... Continue Reading

Biomarker May Help Improve Treatment of Triple-Negative Breast Cancer (September 8, 2015)

Researchers have found a biomarker that appears active in the growth and spread of triple-negative breast cancer. Known as interleukin-13 receptor alpha 2 (IL13Ralpha2), the biomarker may help doctors... Continue Reading

Role of Tumor Size and Estrogen-Receptor Status in Decline in Breast Cancer Deaths (August 4, 2015)

In light of a general decline in breast cancer death since the late 1980s, research has now turned to how type and stage of disease affect survival among different women. These findings, which considered... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS